![]() Tumor treating fields target highly charged proteins essential for cell division. The idea of a cancer-curing device using electrical currents may seem like science fiction. Plus, Novocure assures this treatment won’t disrupt daily routines. Patients use a small device that generates Tumor Treating Fields (TTFs), which might combat cancer. They’re exploring a new cancer treatment method. Novocure is conducting a Phase 3 clinical trial set to conclude in September 2023. Novocure (NASDAQ: NVCR) is trying to change that, and bring more of a therapy that’s no more dangerous than a massage. So, before trial results are out and data gets published, here are three top drug stocks to watch.Ĭhemotherapy has for decades been a difficult and sometimes deadly process. Top drug stocks can surge on a successful phase 1 trial just as much as a phase 3 one. Nevertheless, each trial phase is critical. It’s only the later trials that establish efficacy. Early trials primarily test the drug’s safety for human use. It can also offer insights into the drug’s potential market revenue.įinally, remember that not all clinical trials are the same. Knowledge about the disease, the drug’s mechanism, and previous similar treatments can help assess the drug’s success likelihood. Next, understanding the science behind the drugs is crucial. The top drug stocks to watch usually have imminent successful trials. So, it’s vital for investors to stay informed about these trials. Drug stocks with ongoing clinical trials usually experience significant stock movement based on trial results. However, small cap drug companies also contribute significantly to scientific advancements. Major large cap pharmaceutical firms often dominate the headlines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |